m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study

R. D. Hilgers, S. S. Legha, F. J. Panettiere, David S Alberts

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 x 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 x 3 days q 21 days intravenously. One (5%) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.

Original languageEnglish (US)
Pages (from-to)277-279
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume6
Issue number3
StatePublished - 1983
Externally publishedYes

Fingerprint

Amsacrine
Ovary
Carcinoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study. / Hilgers, R. D.; Legha, S. S.; Panettiere, F. J.; Alberts, David S.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 6, No. 3, 1983, p. 277-279.

Research output: Contribution to journalArticle

@article{749106fac2d24590bbe34fe8080cd950,
title = "m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study",
abstract = "Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 x 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 x 3 days q 21 days intravenously. One (5{\%}) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.",
author = "Hilgers, {R. D.} and Legha, {S. S.} and Panettiere, {F. J.} and Alberts, {David S}",
year = "1983",
language = "English (US)",
volume = "6",
pages = "277--279",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - m-AMSA in epithelial carcinoma of the ovary. A Southwest Oncology Group study

AU - Hilgers, R. D.

AU - Legha, S. S.

AU - Panettiere, F. J.

AU - Alberts, David S

PY - 1983

Y1 - 1983

N2 - Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 x 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 x 3 days q 21 days intravenously. One (5%) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.

AB - Twenty-three patients with advanced heavily pretreated epithelial carcinoma of the ovary were treated with m-AMSA. Eleven patients received a mean of 2.3 courses at a dose of 40 mg/m2 x 3 days q 21 days and 12 patients received a mean of 4.3 courses at a dose of 30 mg/m2 x 3 days q 21 days intravenously. One (5%) partial response in 22 fully evaluable patients was observed. Toxicity was mild and well tolerated. We conclude that m-AMSA is a relatively inactive drug in the treatment of epithelial ovarian carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0020578249&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020578249&partnerID=8YFLogxK

M3 - Article

C2 - 6687779

AN - SCOPUS:0020578249

VL - 6

SP - 277

EP - 279

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -